The Burden of Adverse Drug Reactions: Challenges and Opportunities

---

作者

Amélie Zacharie¹ , Marion Mueller²

1. University of Freiburg
2. Novartis

会议/活动

Regulatory Affairs and Drug Development Master submission, July 2024 (虚拟会议)

海报摘要

This poster underscores the significant costs of adverse drug reactions (ADRs) for all stakeholders and emphasizes the need for collaboration and innovative solutions, such as real-world evidence, OMICS, and AI, to prevent and reduce the impact of ADRs.

关键词

Adverse Drug Reaction, Pharmacovigilance, Real-world evidence, OMICS, AI, Health System

研究领域

Pharmacy and Pharmacology

参考文献

1. Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-53. doi:10.1001/jama.2020.1166.
2. van der Hooft CS, Dieleman JP, Siemes C, Aarnoudse AJ, Verhamme KM, Stricker BH et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf. 2008;17(4):365-71. doi:10.1002/pds.1565.
3. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15-9. doi:10.1136/bmj.329.7456.15.
4. Schurig AM, Bohme M, Just KS, Scholl C, Dormann H, Plank-Kiegele B et al. Adverse Drug Reactions (ADR) and Emergencies. Dtsch Arztebl Int. 2018;115(15):251-8. doi:10.3238/arztebl.2018.0251.
5. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-World Evidence - What Is It and What Can It Tell Us? N Engl J Med (2016) 375(23):2293-7. Epub 2016/12/14. doi: 10.1056/NEJMsb1609216.
6. Collins FS, Varmus H. A New Initiative on Precision Medicine. N Engl J Med (2015) 372(9):793-5. Epub 2015/01/31. doi: 10.1056/NEJMp1500523.
7. Topol EJ. High-Performance Medicine: The Convergence of Human and Artificial Intelligence. Nat Med (2019) 25(1):44-56. Epub 2019/01/09. doi: 10.1038/s41591-018-0300-7.

基金

暂无数据

补充材料

暂无数据

附加信息

利益冲突

Marion Mueller is a full-time employee of Novartis Pharma AG and contributor to IMI ConcePTION, which is a public-private consortium funded by the European Government and the European Federation of Pharmaceutical Industry Associations. Amélie Zacharie has no competing interests.

数据可用性声明

Data sharing not applicable to this poster as no datasets were generated or analyzed during the current study.

知识共享许可协议

Copyright © 2024 Zacharie et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.